RT @ericdeinmd: Jonathan Kay on #RNL2023: Biosimilar is well-researched with cost savings These savings should benefit t
Tweet Content
Jonathan Kay on #RNL2023:
Biosimilar is well-researched with cost savings
These savings should benefit the patients
Incentives for physicians as well in form of decreased prior auth burdens
@RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off